N@N

David Lebowitz Maintained (ALNY) at Buy with Decreased Target to $210 on, Feb 23rd, 2022

David Lebowitz of Morgan Stanley, Maintained "Alnylam Pharmaceuticals, Inc." (ALNY) at Buy with Decreased Target from $215 to $210 on, Feb 23rd, 2022.

David has made no other calls on ALNY in the last 4 months.

There are 9 other peers that have a rating on ALNY. Out of the 9 peers that are also analyzing ALNY, 1 agrees with David's Rating of Hold. Following is the relevant analyst calls for the last 4 months

---

• Mani Foroohar of "SVB Leerink" Maintained at Hold with Decreased Target to $103 on, Friday, February 11th, 2022

These are the ratings of the 8 analyists that currently disagree with David

---

• Etzer Darout of "Guggenheim" Upgraded from Hold to Strong Buy and Held Target at $170 on, Thursday, February 3rd, 2022
• Patrick Trucchio of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $350 on, Thursday, January 20th, 2022
• Edward Tenthoff of "Piper Sandler" Upgraded from Hold to Buy and Increased Target to $208 on, Monday, January 3rd, 2022
• Joseph Stringer of "Needham" Maintained at Strong Buy with Increased Target to $205 on, Monday, November 22nd, 2021
• Salveen Richter of "Goldman Sachs" Upgraded from Hold to Strong Buy and Held Target at $273 on, Monday, November 22nd, 2021
• Luca Issi of "RBC Capital" Upgraded from Hold to Buy and Increased Target to $225 on, Monday, November 22nd, 2021
• Leland Gershell of "Oppenheimer" Upgraded from Hold to Buy and Held Target at $200 on, Monday, November 1st, 2021
• Keay Nakae of "Chardan Capital" Maintained at Strong Buy with Increased Target to $200 on, Friday, October 29th, 2021

Contributing Sources

---